- Home
- AMLX vs ARQT Comparison
AMLX vs ARQT Comparison
Compare AMLX & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMLX | ARQT |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.2B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMLX | ARQT |
|---|---|---|
| Price | $29.85 | $27.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $21.56 | ★ $34.00 |
| AVG Volume (30 Days) | 1.4M | ★ 2.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 65.46 | ★ 88.79 |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $380,786,000.00 | $376,072,000.00 |
| Revenue This Year | N/A | $34.85 |
| Revenue Next Year | N/A | $29.39 |
| P/E Ratio | ★ N/A | $898.17 |
| Revenue Growth | ★ 1612.94 | 91.34 |
| 52 Week Low | $10.83 | $18.62 |
| 52 Week High | $41.14 | $31.77 |
Technical Indicators
Market Signals| Indicator | AMLX | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 59.00 |
| Support Level | $12.54 | $24.91 |
| Resistance Level | $34.35 | $28.18 |
| Average True Range (ATR) | 1.56 | 1.42 |
| MACD | -0.83 | 0.35 |
| Stochastic Oscillator | 18.79 | 80.73 |
Price Performance
Historical ComparisonAbout AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.